Ardea Biosciences, Inc

Valeant Research and Development

Ribapharm Inc.

Ardes Biosciences Inc.

Jean-Luc Girardet

Zhi Hong

Esmir Gunic

Yung-Hyo Koh

Martha Alicia De La Rosa

Barry D Quart

Stanley Lang

David A Paisner

Stephanie Shaw

Li-Tain Yeh

Jean-Michel Andre Vernier

Hong Woo Kim

Jeffrey Miner

Martina E Tedder

Irina Zamansky

Johnson Lau

Laszlo R Treiber

Gabriel Galvin

Kanda Ramasamy

Woo-Hong Kim

Guangyi Wang

Zbigniew Pietrzkowski

Haoyun An

Robert L Orr

Stuart Dimock

Colin Edward Rowlings

Jeff Miner

Hong-Woo Kim

Karen Watson

Yung Hyo Koh

Jae Hoon Shim

Shahul Nilar

Robert Hamatake

Stanley A Lang

Zhijun Zhang

Hongwoo Kim

Nanhua Yao

Jean-Michel Vernier

Stanley Valeant Research & Development Lang

Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.

Compounds and compositions and methods of use

Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.

Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof

Sodium 2-(5-bromo-4-(4-cyclopropyl-naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate is described. In addition, pharmaceutical compositions and uses such compositions for the treatment of a variety of diseases and conditions.

Treatment of gout

Sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate is described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are described.

Treatment of gout and hyperuricemia

A series of S-triazolyl &#x3b1;-mercaptoacetanilides having general structure (1) are provided, where Q is COH, CONR, SOH, or SONR. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections. 

S-Triazolyl alpha-mercapto acetanilides as inhibitors of HIV reverse transcriptase

This invention concerns N-(2-arylamino) aryl sulfonamide compounds which are inhibitors of MEK including crystalline polymorphic forms which exhibit a specific powder x-ray diffraction profile and/or a specific differential scanning calorimetry profile. This invention also concerns pharmaceutical compositions comprising the compounds described herein and methods of use of the compounds and compositions described herein, including the use in the treatment and/or prevention of cancer, hyperproliferative diseases and inflammatory conditions. The invention also concerns methods of making the compounds and compositions described herein.

Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same

Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.

Compounds, compositions and methods of using same for modulating uric acid levels

A series of S-triazolyl &#x3b1;-mercaptoacetanilides having N-(&#x3b1;-mercaptoacetyl) p amino benzoic acid derivatives. are provided, where Q is COH, or a salt or ester thereof, or a C(O) N-linked amino acid. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.

[object Object]

Crystalline polymorphs and solid mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate are described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are provided.

S-triazolyl &#x3b1;-mercaptoacetanilides as inhibitors of HIV reverse transcriptase

Described herein are compounds useful in the reduction of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, a compound disclosed herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.

Methods of modulating uric acid levels

This application concerns certain 2-phenylamino-6-aryl amino-, 6-aryloxy-, and 6-arylthio-purines, -azapurines and -deazapurines. These compounds are non-nucleoside reverse transcriptase inhibitors and have potential as anti-HIV treatment.

Pyrrolo [2,3-D] pyrimidines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV

Growing community of inventors

San Diego, CA, United States of America

Jean-Luc Girardet